Floatz logo

Campath

AIDS-Associated Lymphoma

National Cancer Institute (NCI)Phase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the AIDS-Associated Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
AIDS Malignancy Consortium
Phase 2BB
PREDNISONE TABLETS
AIDS Malignancy Consortium
Phase 2BB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 2BB
(+)-VINCRISTINE
Ontario Clinical Oncology Group (OCOG)
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Ontario Clinical Oncology Group (OCOG)
Phase 2B
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2B

Same molecule, other indications

Campath is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →